0453 GMT - Citi analyst Mathieu Chevrier would like more details on Ebos's acquisition of pet-medicine provider SVS. Chevrier tells clients in a note that the acquisition is in line with the pharmaceuticals supplier's long-standing M&A strategy, but that the New Zealand-based company didn't provide information on anticipated synergies, capital intensity or how SVS performed prior to the Covid-driven surge in pet ownership. Chevrier expects SVS, combined with Ebos's acquisition of the remaining 10% stake in its Transmedic unit, to be 1%-2% accretive to his fiscal 2026 EPS estimate. Citi has a sell rating and A$32.00 target price on Ebos's Australia-listed stock, which is down 5.1% at A$33.74. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 11, 2025 00:53 ET (04:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。